source
- Experts say Angelman syndrome drug failure leaves hope for similar antisense therapiesUltragenyx announced that its late-stage trial of an experimental Angelman syndrome drug did not meet its primary endpoints, marking a setback for the rare-disease community. Researchers such as M…
- NeuShen Therapeutics raises over $80 million to advance three brain-health drug candidatesNeuShen Therapeutics, a biotech with operations in Shanghai and Boston, announced it has closed a Series B financing round of more than $80 million. The capital will be used to move three clinical…